One of the current controversies in the field of lung cancer is whether we should be doing biopsies routinely when a patient develops progression of their disease, particularly in the setting of acquired resistance to a molecularly targeted therapy.  There are some academic oncologists who favor this approach, but I think there's a very good reason why this isn't and shouldn't be the current standard of care.

[powerpress]

Agree or disagree? I'm interested in hearing opinions from those with the perspective of the patient or caregiver, as well as other physicians who might be involved in these decisions.